Figures & data
Figure 1. Molecular structure of both Cimitidine (I) and Famotidine (II).
Figure 2. Molecular structure of co-crystallized structure AR-A014418.
Figure 3. (A) Detailed view of the co-crystallized structure (AR-A014418) and the corresponding interacting amino-acids within the binding site of GSK-3β. (B) Detailed view of the docked famotidine structure and the corresponding interacting amino-acid moieties within the binding site of GSK-3β.
Figure 4. Comparison between the docked conformer/pose of inhibitor AR-A014418 (dark black) as produced by the docking simulation and the crystallographic structure of this inhibitor within GSK-3β (gray, PDB code: 1Q5K).
Figure 5. Liver glycogen reserves in fasting 10-week old male Balb/c mice three hours after i.p. administration of vehicle control, 1.1, 2.2 and 4.4 mg/kg of famotidine normalized to mice weights (20 g). Each result represents the average glycogen level from 5 mice. Error bars indicate the standard deviations of the measurements. (*) p value < 0.05 versus control.
Figure 6. Glycemic response during a 75 g OGTT (n = 6) in healthy humans with (▴) or without (▪) famotidine (80 mg p.o.). Asterisks denote a significant difference compared to the control values. Data are expressed as geometric mean ± SEM.
